Halozyme Therapeutics, Inc. (HALO) is a publicly traded Healthcare sector company. As of May 21, 2026, HALO trades at $69.49 with a market cap of $8.00B and a P/E ratio of 23.31. HALO moved +0.36% today. Year to date, HALO is -3.12%; over the trailing twelve months it is +29.06%. Its 52-week range spans $42.01 to $82.22. Analyst consensus is strong buy with an average price target of $84.48. Rallies surfaces HALO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Halozyme Therapeutics, Inc. (HALO) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. HALO moved +0.36% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $69.49 |
| Market Cap | $8.00B |
| P/E Ratio | 23.31 |
| EPS | $2.96 |
| Dividend Yield | 0.00% |
| 52-Week High | $82.22 |
| 52-Week Low | $42.01 |
| Volume | 191 |
| Avg Volume | 0 |
| Revenue (TTM) | $1.51B |
| Net Income | $348.84M |
| Gross Margin | 82.79% |
5 analysts cover HALO: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $84.48.